Cargando…

CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers

BACKGROUND: Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT). METHODS: OAT prescriptions were required monthly at one...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwarz, Caroline, Schubert, Raphael, Schwarz, Michael, Schütz, Angelika, Jenke, Anika, Bauer, David, Steinwender, Benjamin, Gutic, Enisa, Reiberger, Thomas, Haltmayer, Hans, Gschwantler, Michael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474458/
https://www.ncbi.nlm.nih.gov/pubmed/37663576
http://dx.doi.org/10.1016/j.jve.2023.100338
_version_ 1785100498262556672
author Schwarz, Caroline
Schubert, Raphael
Schwarz, Michael
Schütz, Angelika
Jenke, Anika
Bauer, David
Steinwender, Benjamin
Gutic, Enisa
Reiberger, Thomas
Haltmayer, Hans
Gschwantler, Michael
author_facet Schwarz, Caroline
Schubert, Raphael
Schwarz, Michael
Schütz, Angelika
Jenke, Anika
Bauer, David
Steinwender, Benjamin
Gutic, Enisa
Reiberger, Thomas
Haltmayer, Hans
Gschwantler, Michael
author_sort Schwarz, Caroline
collection PubMed
description BACKGROUND: Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT). METHODS: OAT prescriptions were required monthly at one of nine approved authorities, making them ideal platforms for hepatitis C virus (HCV) screening. All PWIDs attending these authorities between January 2019 and March 2020 were offered on-site HCV screening, and consecutive HCV RNA PCR in case of positive HCV serology. In HCV viremic PWIDs, offsite referral to HCV care and treatment according to directly observed therapy (DOT) alongside OAT were performed. RESULTS: 4,327/6,665 (64.9%) individuals were contacted before the COVID-19-related project discontinuation. There were 1,538/4,327 (35.5%) individuals who had participated in the study. HCV serology was available in 1,510/1,538 (98.2%): 795/1,519 (52.6%) had a positive serology, among whom 632 (79.5%) were followed-up with a PCR test. In 8/1,538 (0.5%) additional study participants HCV RNA PCR was assessed without prior serological screening. 239/640 (37.3%) individuals were HCV viremic with 51 (21.3%) having started on direct-acting antivirals (DAAs). 48/51 (94.1%) had completed treatment, among whom 42 (87.5% according to ITT) had achieved sustained virologic response at 12 weeks after completing treatment (SVR12) and 6 (12.5%) had been lost to follow-up after completion of therapy (SVR12 according to mITT: 42/42, 100%). No treatment failures had occurred. CONCLUSION: Providing integrated point-of-care HCV screening/diagnostic testing at central OAT approved centers, followed by DOT with DAAs, represents an effective HCV microelimination strategy. While some PWIDs were lost in the cascade to cure and the absolute number of SVR was limited by the COVID-19 pandemic, our approach will allow linkage to care in a large proportion of Viennese PWIDs.
format Online
Article
Text
id pubmed-10474458
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104744582023-09-03 CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers Schwarz, Caroline Schubert, Raphael Schwarz, Michael Schütz, Angelika Jenke, Anika Bauer, David Steinwender, Benjamin Gutic, Enisa Reiberger, Thomas Haltmayer, Hans Gschwantler, Michael J Virus Erad Original Research BACKGROUND: Hepatitis C remains highly prevalent among people who inject drugs (PWIDs). We propose an integrated approach for screening/diagnostic testing and treatment in 6,665 Viennese PWIDs registered to access opioid agonist therapy (OAT). METHODS: OAT prescriptions were required monthly at one of nine approved authorities, making them ideal platforms for hepatitis C virus (HCV) screening. All PWIDs attending these authorities between January 2019 and March 2020 were offered on-site HCV screening, and consecutive HCV RNA PCR in case of positive HCV serology. In HCV viremic PWIDs, offsite referral to HCV care and treatment according to directly observed therapy (DOT) alongside OAT were performed. RESULTS: 4,327/6,665 (64.9%) individuals were contacted before the COVID-19-related project discontinuation. There were 1,538/4,327 (35.5%) individuals who had participated in the study. HCV serology was available in 1,510/1,538 (98.2%): 795/1,519 (52.6%) had a positive serology, among whom 632 (79.5%) were followed-up with a PCR test. In 8/1,538 (0.5%) additional study participants HCV RNA PCR was assessed without prior serological screening. 239/640 (37.3%) individuals were HCV viremic with 51 (21.3%) having started on direct-acting antivirals (DAAs). 48/51 (94.1%) had completed treatment, among whom 42 (87.5% according to ITT) had achieved sustained virologic response at 12 weeks after completing treatment (SVR12) and 6 (12.5%) had been lost to follow-up after completion of therapy (SVR12 according to mITT: 42/42, 100%). No treatment failures had occurred. CONCLUSION: Providing integrated point-of-care HCV screening/diagnostic testing at central OAT approved centers, followed by DOT with DAAs, represents an effective HCV microelimination strategy. While some PWIDs were lost in the cascade to cure and the absolute number of SVR was limited by the COVID-19 pandemic, our approach will allow linkage to care in a large proportion of Viennese PWIDs. Elsevier 2023-07-27 /pmc/articles/PMC10474458/ /pubmed/37663576 http://dx.doi.org/10.1016/j.jve.2023.100338 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Schwarz, Caroline
Schubert, Raphael
Schwarz, Michael
Schütz, Angelika
Jenke, Anika
Bauer, David
Steinwender, Benjamin
Gutic, Enisa
Reiberger, Thomas
Haltmayer, Hans
Gschwantler, Michael
CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers
title CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers
title_full CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers
title_fullStr CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers
title_full_unstemmed CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers
title_short CHIME - A tailored HCV microelimination project in Viennese people who inject drugs at drug centralized substitution centers
title_sort chime - a tailored hcv microelimination project in viennese people who inject drugs at drug centralized substitution centers
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10474458/
https://www.ncbi.nlm.nih.gov/pubmed/37663576
http://dx.doi.org/10.1016/j.jve.2023.100338
work_keys_str_mv AT schwarzcaroline chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters
AT schubertraphael chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters
AT schwarzmichael chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters
AT schutzangelika chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters
AT jenkeanika chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters
AT bauerdavid chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters
AT steinwenderbenjamin chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters
AT guticenisa chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters
AT reibergerthomas chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters
AT haltmayerhans chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters
AT gschwantlermichael chimeatailoredhcvmicroeliminationprojectinviennesepeoplewhoinjectdrugsatdrugcentralizedsubstitutioncenters